| Methods |
2‐week washout period; 2‐ to 4‐week single‐blind placebo run‐in; inclusion criteria= mean sitting DBP 95‐110 mm Hg; 8‐week double‐blind treatment |
| Participants |
Irbesartan 150 mg: n=134(66 males,68 females); mean age=56.1(11.8) years; baseline sitting SBP=152.8(11.2) mm Hg, DBP=99.4(4.0) mm Hg, HR=72.9(7.9) bpm;
Placebo: n=131(64 males,67 females); mean age=57.1(12.0) years; baseline sitting SBP=152.3(12.1) mm Hg, DBP=98.9(3.3) mm Hg, HR=72.8(9.2) bpm |
| Interventions |
Irbesartan 150 mg once daily;
Placebo;
taken with water at approximately 8 AM |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change reported, endpoint BP and SD reported, BP data from Table 2, p. 1015; Jadad Score=4; funding source= Novartis |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
